PF
Pfizer
PFE·NYSENew York NYFounded 184983,000 employees
Large CappharmaPublicOncologyInfectious DiseaseDermatologyRare Disease
Platform: SM & Biologics
Market Cap
$150B
All Drugs
14
Clinical Trials
23
Failed / Terminated
5
FDA Approved
1
Stock Price & Catalysts (PFE)
Loading PFE stock data...
Drug Pipeline (14 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| PFE-3703 | PFE-3703 | Phase 1/2 | 2 | CDK2 | TTR AmyloidosisDravet | ||
| PFE-5501 | PFE-5501 | Phase 1 | 2 | BTK | Alzheimer'sRCC | ||
| PFE-8662 | PFE-8662 | NDA/BLA | 1 | CD19 | NBMigraine | ||
| PFE-2901 | PFE-2901 | Phase 2 | 2 | AHR | SMACLL | ||
| PFE-7550 | PFE-7550 | Phase 3 | 3 | Aβ | Asthma | ||
| PFE-1944 | PFE-1944 | NDA/BLA | 1 | APOC3 | PBC | ||
| PFE-1085 | PFE-1085 | Preclinical | 1 | FXIa | DLBCL | ||
| PFE-2191 | PFE-2191 | NDA/BLA | 1 | GLP-1R | MCC | ||
| PFE-7809 | PFE-7809 | Phase 1 | 1 | DLL3 | Huntington's | ||
| PFE-5767 | PFE-5767 | Phase 1/2 | 2 | BET | MCLEwing Sarcoma | ||
| Terafutibatinib | PFE-3646 | Phase 1/2 | 2 | CD38 | CeliacGastric Ca | ||
| Miriosocimab | PFE-5213 | Phase 1 | 2 | PARP | DravetBreast Ca | ||
| Sotovorutinib | PFE-6253 | Approved | 1 | Aβ | MDS | ||
| Voxacilimab | PFE-856 | Phase 2 | 2 | TYK2 | PV |
SEC Filings & Financial Documents
Insider Trading Activity
Fetching insider trading data from SEC EDGAR...
Catalyst Events (19)